Cerevel Therapeutics Holdings, Inc. was an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.
[7] In December 2023, American pharmaceutical company AbbVie announced its intention to acquire Cerevel for US$8.7 billion.
[11][better source needed][12] Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies.
Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more.
[19] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types.